There are several barriers to wider access to genomic testing in Europe

Lack of value recognition

Time to market delays

Lack of infrastructure

• The value of advanced diagnostics is not sufficiently recognised.

• Funding is insufficient and support not well suited to increase their role in the clinical setting.

• The time to market for advanced diagnostics is too long, complex and fraught with uncertainty.

• There is a lack of pathways to appraisal that are time-bound and flexible and that can accommodate the unique characteristics of advanced diagnostics.

• Essential clinical supporting infrastructure - including appropriately trained workforce, data sharing and data storage infrastructure capabilities, and digital health recording within healthcare systems - is lacking in Europe.

Out of the 279 genetics and genomics companies worldwide, over 63% (176) are currently based in the US, compared to 21% located in Europe

Percentage of genomics companies by location
(region/country)